Yanina Grant-Huerta
CIK: 0002064348
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Aug 14, 2026IMA
ImageneBio, Inc.
Award(A)Direct39K shares- - Aug 14, 2026IMA
ImageneBio, Inc.
Award(A)Direct65K shares- - May 18, 2026ATRA
Atara Biotherapeutics, Inc.
Sale(S)Direct2.4K shares at avg. $9.13$22K - Mar 9, 2026ATRA
Atara Biotherapeutics, Inc.
Award(A)Direct20.3K shares- - Mar 2, 2026ATRA
Atara Biotherapeutics, Inc.
Sale(S)Direct24 shares at avg. $5.08$121.848 - Mar 2, 2026ATRA
Atara Biotherapeutics, Inc.
Sale(S)Direct1.6K shares at avg. $5.08$8K - Mar 2, 2026ATRA
Atara Biotherapeutics, Inc.
Sale(S)Direct377 shares at avg. $5.08$2K - Mar 2, 2026ATRA
Atara Biotherapeutics, Inc.
Sale(S)Direct100 shares at avg. $5.08$508.3 - Nov 17, 2025ATRA
Atara Biotherapeutics, Inc.
Sale(S)Direct1.6K shares at avg. $13.19$22K - Nov 17, 2025ATRA
Atara Biotherapeutics, Inc.
Sale(S)Direct85 shares at avg. $13.19$1K - Nov 17, 2025ATRA
Atara Biotherapeutics, Inc.
Sale(S)Direct74 shares at avg. $13.19$976.134 - Aug 18, 2025ATRA
Atara Biotherapeutics, Inc.
Sale(S)Direct55 shares at avg. $11.61$638.495 - Aug 18, 2025ATRA
Atara Biotherapeutics, Inc.
Sale(S)Direct86 shares at avg. $11.61$998.718 - Aug 18, 2025ATRA
Atara Biotherapeutics, Inc.
Sale(S)Direct1.7K shares at avg. $11.61$19K - May 16, 2025ATRA
Atara Biotherapeutics, Inc.
Sale(S)Direct2.2K shares at avg. $6.76$15K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 14, 2026 |  IMA ImageneBio, Inc. | Award(A) | 39,000 | - | $0 | Direct |
| Aug 14, 2026 | IMA ImageneBio, Inc. | Award(A) | 65,000 | - | $0 | Direct |
| May 18, 2026 |  ATRA Atara Biotherapeutics, Inc. | Sale(S) | 2,414 | $9.13 | $22,036 | Direct |
| Mar 9, 2026 | ATRA Atara Biotherapeutics, Inc. | Award(A) | 20,300 | - | $0 | Direct |
| Mar 2, 2026 | ATRA Atara Biotherapeutics, Inc. | Sale(S) | 24 | $5.08 | $122 | Direct |
| Mar 2, 2026 | ATRA Atara Biotherapeutics, Inc. | Sale(S) | 1,603 | $5.08 | $8,145 | Direct |
| Mar 2, 2026 | ATRA Atara Biotherapeutics, Inc. | Sale(S) | 377 | $5.08 | $1,916 | Direct |
| Mar 2, 2026 | ATRA Atara Biotherapeutics, Inc. | Sale(S) | 100 | $5.08 | $508 | Direct |
| Nov 17, 2025 | ATRA Atara Biotherapeutics, Inc. | Sale(S) | 1,645 | $13.19 | $21,691 | Direct |
| Nov 17, 2025 | ATRA Atara Biotherapeutics, Inc. | Sale(S) | 85 | $13.19 | $1,121 | Direct |
| Nov 17, 2025 | ATRA Atara Biotherapeutics, Inc. | Sale(S) | 74 | $13.19 | $976 | Direct |
| Aug 18, 2025 | ATRA Atara Biotherapeutics, Inc. | Sale(S) | 55 | $11.61 | $638 | Direct |
| Aug 18, 2025 | ATRA Atara Biotherapeutics, Inc. | Sale(S) | 86 | $11.61 | $999 | Direct |
| Aug 18, 2025 | ATRA Atara Biotherapeutics, Inc. | Sale(S) | 1,668 | $11.61 | $19,372 | Direct |
| May 16, 2025 | ATRA Atara Biotherapeutics, Inc. | Sale(S) | 2,218 | $6.76 | $15,000 | Direct |
1-15 of 15 transactions
About Grant-Huerta Yanina
Grant-Huerta Yanina (SEC CIK 0002064348) files insider reports with the SEC as Chief Financial Officer of ImageneBio, Inc. (IMA) and Chief Accounting Officer of Atara Biotherapeutics, Inc. (ATRA).
Signal8 holds 9 ownership filings by Grant-Huerta Yanina (2 Form 3, 7 Form 4), filed between Apr 10, 2025 and Aug 17, 2026. Those filings report 15 transactions, from May 16, 2025 to Aug 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Grant-Huerta Yanina's filings is in SAN DIEGO, CA.
Recent filings by Grant-Huerta Yanina
- Aug 14, 2026: Grants or awards of IMA shares (2 lines, Form 4, code A).
- May 18, 2026: Open-market sale of ATRA shares (Form 4, code S).
- Mar 9, 2026: Grant or award of ATRA shares (Form 4, code A).
- Mar 2, 2026: Open-market sales of ATRA shares (4 lines, Form 4, code S).
- Nov 17, 2025: Open-market sales of ATRA shares (3 lines, Form 4, code S).
Other insiders filing for ImageneBio, Inc. (IMA)
- Yarema Kristin, Chief Executive Officer
- Lally Robert B, Principal Accounting Officer
- Wang Jonathan Jian, Director
- Stampacchia Otello, Director
- SLATTERY JOSEPH P, Director
- Bonita David P, Director